“Effects of Semaglutide in HIV-Associated Lipohypertrophy”
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. A similarly-designed study will enroll overweight/obese participants without HIV who will match the participants with HIV by gender, age, and BMI, and will run in parallel to the HIV study. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment.
Drug - Semaglutide Injectable Product
semaglutide subcutaneous injection
Drug - Placebo
Effects of GLP-l Receptor Agonists on Cardiometabolic Alterations in HIV-associated Lipohypertrophy